Abstract
ABSTRACT Radioactive iodine (RAI) has been used in the treatment of differentiated thyroid cancer (DTC) since many decades. However, there is growing evidence to suggest that RAI may be avoided in low-risk group and is recommended in intermediate and high risk categories of DTC. This article incorporates literature review followed by a consensus of experts to conclude the role of RAI in DTC. The goals of RAI treatment, patient preparation, selection, and doses of RAI treatment in various risk categories are discussed. The follow-up after RAI treatment, side effects, and contraindications to RAI treatment are explained.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callMore From: Journal of Head & Neck Physicians and Surgeons
Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
